The Role of ddPCR in CML

By Kerri Fitzgerald - Last Updated: November 14, 2022

Blood Cancers Today Associate Editor Jerald Radich, MD, discusses the role of ddPCR for CML in the age of targeted therapies. He spoke with Blood Cancers Today about the topic ahead of the presentation at the SOHO Annual Meeting.

Post Tags:SOHO 2022

Continuous Medicaid Coverage Associated With Lower Incidence of Stage IV Lymphoma Among Children and Young Adults

Melissa BadamoAggressive B-Cell Lymphoma | May 27, 2025

Steady access to Medicaid insurance helps ensure early recognition of symptoms, said senior author Xu Ji, PhD.

Controversies and Unanswered Questions in CLL

Ryan W. Jacobs, MDChronic Myeloid Leukemia | May 22, 2025

Experts debate frontline CLL therapy—time-limited combos vs long-term BTKi—and the role of MRD in treatment decisions.

Study Finds Link Between Gut Health and Leukemia Risk

Melissa BadamoAcute Myeloid Leukemia | May 19, 2025

ADP-heptose in the intestines of older individuals accelerates the expansion of pre-leukemic blood cells.

Oncologists Are Resigning at Unprecedented Rates: Are Academic Medical Centers Ready to Respond?

Melissa BadamoAcute Lymphoblastic Leukemia | May 16, 2025

Studies have shown that oncologists are leaving the workforce at increasing rates in association with growing workloads.

Evolving CLL Treatment in 2025: Optimal Strategies Explained

Ryan W. Jacobs, MDChronic Myeloid Leukemia | May 14, 2025

Ryan Jacobs, MD discusses 2025 CLL treatment advances, including BTK/BCL-2 combos, resistance, and time-defined strategies.

The Role of ddPCR in CML

Related Posts